Fresenius Medical Care (NYSE:FMS) Coverage Initiated at StockNews.com

Analysts at StockNews.com began coverage on shares of Fresenius Medical Care (NYSE:FMS) in a research report issued on Friday. The brokerage set a “strong-buy” rating on the stock.

Separately, Truist Financial boosted their price objective on Fresenius Medical Care from $22.00 to $23.00 and gave the company a “hold” rating in a research report on Monday, October 7th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, one has issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, Fresenius Medical Care presently has an average rating of “Hold” and a consensus price target of $23.00.

Fresenius Medical Care Trading Up 2.3 %

Shares of NYSE FMS opened at $19.54 on Friday. Fresenius Medical Care has a twelve month low of $16.46 and a twelve month high of $22.76. The stock has a market cap of $11.47 billion, a price-to-earnings ratio of 21.96, a P/E/G ratio of 1.11 and a beta of 0.91. The company has a quick ratio of 1.09, a current ratio of 1.46 and a debt-to-equity ratio of 0.45. The company’s fifty day moving average is $20.32 and its 200-day moving average is $20.17.

Fresenius Medical Care (NYSE:FMS) last posted its earnings results on Tuesday, July 30th. The company reported $0.38 earnings per share for the quarter, hitting the consensus estimate of $0.38. Fresenius Medical Care had a return on equity of 5.48% and a net margin of 2.72%. The firm had revenue of $5.13 billion for the quarter, compared to analyst estimates of $5.28 billion. Equities research analysts predict that Fresenius Medical Care will post 1.52 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the company. Allworth Financial LP boosted its position in Fresenius Medical Care by 53.1% during the 3rd quarter. Allworth Financial LP now owns 1,675 shares of the company’s stock worth $36,000 after acquiring an additional 581 shares during the last quarter. GAMMA Investing LLC boosted its holdings in Fresenius Medical Care by 50.4% during the third quarter. GAMMA Investing LLC now owns 4,998 shares of the company’s stock worth $106,000 after purchasing an additional 1,675 shares during the last quarter. ORG Partners LLC bought a new position in Fresenius Medical Care in the first quarter valued at $110,000. ORG Wealth Partners LLC acquired a new stake in Fresenius Medical Care in the 3rd quarter valued at $112,000. Finally, SageView Advisory Group LLC bought a new stake in Fresenius Medical Care during the 1st quarter worth about $127,000. 8.25% of the stock is currently owned by institutional investors.

Fresenius Medical Care Company Profile

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.